Philochem AG, and Blue Earth Diagnostics, a Bracco company engaged in the development and commercialization of innovative PET radiopharmaceuticals, provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics.
The
collaboration encompasses the development of OncoFAP, a proprietary, small
organic ligand with ultra-high affinity to Fibroblast Activation Protein (FAP),
for applications in the diagnostic imaging of solid tumors.
Under
the agreement, the Philogen Group is conducting a Phase 1 clinical study to
evaluate the safety and dosimetry of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA)
in patients with solid tumors. The agreement provides Blue Earth Diagnostics with
the rights to develop and commercialize 68Ga- OncoFAP worldwide.
To read more please visit:
Source: Philochem